BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
BioNexus Gene Lab Corp. (NASDAQ: BGLC) announces a successful co-investment by the Securities Commission of Malaysia's Malaysia Co-Investment Fund (MyCIF) in Ascension Innovation Sdn Bhd (AISB). This follows BGLC's recent investment in AISB under the Environmental & Social Impact (ESI) Scheme. AISB, a healthcare technology company, is the first to receive investment under the ESI scheme, which supports impactful small and medium enterprises.
The co-investment will accelerate AISB's AI-driven healthcare solutions, particularly its aiCMS platform, designed to enhance clinical management and patient care across Malaysia. This partnership aims to advance the 'One Patient, One Record' initiative under Malaysia's National Electronic Medical Records (EMR) Plan. The total investment in this round amounts to RM1.7 million (approx. USD 390k).
BioNexus Gene Lab Corp. (NASDAQ: BGLC) annuncia un co-investimento riuscito da parte della Securities Commission of Malaysia attraverso il Malaysia Co-Investment Fund (MyCIF) in Ascension Innovation Sdn Bhd (AISB). Questo seguito all'investimento recente di BGLC in AISB nell'ambito dello schema Environmental & Social Impact (ESI). AISB, un'azienda di tecnologia sanitaria, è la prima a ricevere investimenti sotto lo schema ESI, che supporta le piccole e medie imprese con impatti significativi.
Il co-investimento accelererà le soluzioni sanitarie basate sull'AI di AISB, in particolare la sua piattaforma aiCMS, progettata per migliorare la gestione clinica e la cura del paziente in tutta la Malaysia. Questo partenariato mira a promuovere l'iniziativa 'Un Paziente, Un Registro' nell'ambito del Piano Nazionale per i Registri Elettronici Sanitari (EMR) della Malaysia. L'investimento totale in questo round ammonta a RM1.7 milioni (circa USD 390k).
BioNexus Gene Lab Corp. (NASDAQ: BGLC) anuncia una inversión conjunta exitosa por parte de la Securities Commission of Malaysia a través del Malaysia Co-Investment Fund (MyCIF) en Ascension Innovation Sdn Bhd (AISB). Esto sigue a la reciente inversión de BGLC en AISB bajo el esquema de Impacto Ambiental y Social (ESI). AISB, una empresa de tecnología sanitaria, es la primera en recibir inversión bajo el esquema ESI, que apoya a pequeñas y medianas empresas de gran impacto.
La inversión conjunta acelerará las soluciones de salud impulsadas por IA de AISB, particularmente su plataforma aiCMS, diseñada para mejorar la gestión clínica y la atención al paciente en toda Malasia. Esta asociación tiene como objetivo avanzar la iniciativa 'Un Paciente, Un Registro' en el marco del Plan Nacional de Registros Electrónicos de Salud (EMR) de Malasia. La inversión total en esta ronda asciende a RM1.7 millones (aproximadamente USD 390k).
BioNexus Gene Lab Corp. (NASDAQ: BGLC)는 말레이시아 증권위원회의 말레이시아 공동 투자 기금(MyCIF)이 Ascension Innovation Sdn Bhd(AISB)에 성공적인 공동 투자 발표를 했습니다. 이는 BGLC가 환경 및 사회적 영향(ESI) 제도에 따라 AISB에 최근 투자한 후의 일입니다. AISB는 의미 있는 중소기업을 지원하는 ESI 제도 아래에서 투자를 받는 첫 번째 헬스케어 기술 기업입니다.
이번 공동 투자는 AISB의 AI 기반 헬스케어 솔루션, 특히 말레이시아 전역의 임상 관리 및 환자 치료를 향상시키기 위해 설계된 aiCMS 플랫폼을 가속화할 것입니다. 이 파트너십은 말레이시아의 국가 전자 의료 기록(EMR) 계획 하에 '하나의 환자, 하나의 기록' 이니셔티브를 발전시키는 것을 목표로 하고 있습니다. 이번 투자 라운드의 총 투자액은 RM1.7 백만(약 39만 달러)입니다.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) annonce un co-investissement réussi de la part de la Securities Commission of Malaysia via le Malaysia Co-Investment Fund (MyCIF) dans Ascension Innovation Sdn Bhd (AISB). Cela fait suite à l'investissement récent de BGLC dans AISB dans le cadre du schéma d'Impact Environnemental et Social (ESI). AISB, une entreprise de technologie de la santé, est la première à recevoir un investissement dans le cadre du schéma ESI, qui soutient les petites et moyennes entreprises ayant un impact significatif.
Le co-investissement permettra d'accélérer les solutions de santé basées sur l'IA d'AISB, en particulier sa plateforme aiCMS, conçue pour améliorer la gestion clinique et les soins aux patients à travers la Malaisie. Ce partenariat vise à faire avancer l'initiative 'Un Patient, Un Dossier' dans le cadre du Plan National des Dossiers Médicaux Électroniques (EMR) de Malaisie. L'investissement total de ce tour s'élève à RM1,7 million (environ 390 000 USD).
BioNexus Gene Lab Corp. (NASDAQ: BGLC) kündigt eine erfolgreiche Co-Investition der Securities Commission of Malaysia über den Malaysia Co-Investment Fund (MyCIF) in die Ascension Innovation Sdn Bhd (AISB) an. Dies folgt auf die jüngste Investition von BGLC in AISB im Rahmen des Umwelt- und Sozialimpact-Schemas (ESI). AISB, ein Unternehmen für Gesundheitstechnologie, ist das erste, das eine Investition aus dem ESI-Schema erhält, das bedeutende kleine und mittlere Unternehmen unterstützt.
Die Co-Investition wird die KI-gesteuerten Gesundheitslösungen von AISB, insbesondere die aiCMS-Plattform, die darauf ausgelegt ist, das klinische Management und die Patientenversorgung in ganz Malaysia zu verbessern, beschleunigen. Diese Partnerschaft zielt darauf ab, die Initiative 'Ein Patient, Ein Datensatz' im Rahmen des nationalen elektronischen Gesundheitsaktenplans (EMR) Malaysias voranzubringen. Die Gesamtinvestition in dieser Runde beläuft sich auf RM1,7 Millionen (etwa 390.000 USD).
- Successful co-investment from Securities Commission of Malaysia (MyCIF) in AISB
- AISB becomes first recipient of investment under the ESI scheme
- Total investment round reaches RM1.7 million (approx. USD 390k)
- Acceleration of AI-driven healthcare solutions deployment
- None.
Insights
The Securities Commission of Malaysia's co-investment in Ascension Innovation Sdn Bhd (AISB) via the MyCIF fund is a positive development for BioNexus Gene Lab Corp. (BGLC). This move validates BGLC's investment strategy and potentially enhances the value of their stake in AISB. The total investment of
AISB's selection as the first recipient under the Environmental & Social Impact (ESI) scheme is noteworthy. Their aiCMS platform, integrating predictive analytics and generative AI for clinical management, aligns with global trends in healthcare digitalization. The 'One Patient, One Record' initiative under Malaysia's National EMR Plan could significantly improve healthcare efficiency and patient outcomes. However, the success of such systems depends on factors like interoperability, data security and clinician adoption. Investors should monitor AISB's progress in addressing these challenges and its ability to scale the solution nationally. The co-investment could accelerate development, but the timeline for widespread implementation and revenue generation remains uncertain.
This co-investment signals growing government support for healthcare technology in Malaysia, potentially creating a favorable market environment for companies like BGLC and AISB. The ESI scheme's focus on impactful solutions for SMEs could open doors for further investments in the sector. However, investors should be aware that the healthcare technology market in Southeast Asia is becoming increasingly competitive. AISB's success will depend on its ability to differentiate its offerings and execute effectively. While the news is positive, it's important to assess BGLC's overall portfolio and financial performance, as this single investment may not significantly impact the company's near-term prospects. The long-term potential hinges on AISB's ability to capture a substantial market share in Malaysia's evolving healthcare landscape.
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction and potential of AISB.
AISB, a pioneering healthcare technology company, has become the first issuer to receive investment under the Environmental & Social Impact (ESI) scheme, part of the broader MyCIF initiative. This scheme, designed to support small and medium enterprises (MSMEs) with impactful solutions, aligns perfectly with AISB’s mission to revolutionize healthcare through innovative, sustainable practices.
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp., commented, “We are honored to have the Securities Commission Malaysia through it’s MyCIF Fund, co-invest in Ascension Innovation Sdn Bhd. This collaboration is not only a testament to the robust potential of AISB’s technology but also reflects the confidence in our strategic investment decisions. The support from MyCIF will significantly bolster AISB's efforts to advance the ‘One Patient, One Record’ initiative under Malaysia's National Electronic Medical Records (EMR) Plan, a critical step towards modernizing the nation’s healthcare infrastructure.”
The co-investment will empower AISB to accelerate the deployment of its AI-driven healthcare solutions, particularly through its flagship platform, aiCMS. This platform is designed to integrate predictive analytics and generative AI to enhance clinical management and patient care across Malaysia.
“This investment partnership represents a milestone in our collective vision to create a more sustainable, efficient healthcare system,” said Andrew Teng, CEO of Ascension Innovation Sdn Bhd. “We are committed to leveraging this support to achieve our goals and contribute meaningfully to Malaysia's healthcare transformation.”
The MyCIF investment is a significant milestone for AISB and BGLC, reflecting the growing importance of sustainable and impactful healthcare innovations in the digital age, bringing the total investment in this round to RM1.7 million (approx. USD 390k).
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) is an emerging leader in RNA-based genomic diagnostics, committed to advancing personalized medicine and improving global health outcomes.
For more information, visit www.bionexusgenelab.com.
About Ascension Innovation Sdn Bhd
Ascension Innovation Sdn Bhd is a leading healthcare technology company focused on innovative AI-driven solutions. Visit www.aisb.io for more details.
Investor Relations
BioNexus Gene Lab Corporation
Email: ir@bionexusgenelab.com
FAQ
What is the significance of the MyCIF co-investment for BioNexus Gene Lab Corp. (BGLC)?
How much is the total investment in AISB's current funding round?
What is the main focus of AISB's technology that BGLC has invested in?
How does the investment in AISB align with Malaysia's healthcare initiatives?
